×
About 1,670,852 results

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
https://www.scripps.edu/_files/pdfs/news-and-events/The D614G mutation in the SARS-CoV-2 spike protein reduces S1.pdf

SARS coronavirus 2 (SARS-CoV-2) isolates encoding a D614G mutation in the viral spike (S) protein predominate over time in locales where it is found, implying that this change enhances viral transmission. We therefore compared the functional properties of the S proteins with aspartic acid (SD614) and glycine (SG614) at residue 614. We observed that retroviruses pseudotyped with SG614 infect...

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma
https://www.onclive.com/view/dr-richardson-on-phase-1-data-with-cc92480-in-multiple-myeloma

May 31st, 2020

SARS-CoV-2 and Nervous System - Neurological Manifestations in Patients With COVID-19: A Systematic Review
https://www.neurores.org/index.php/neurores/article/view/602/580

Coronavirus (CoV) is a virus infectious disease with a considerable spectrum of clinical presentations. Symptoms ranged from asymptomatic infection to severe pneumonia that may lead to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and several clinical complications. Neurologic symptoms related to CoV have been described recently in the literature. The relationship between SARS-Co...

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study
https://link.springer.com/article/10.1007/s10072-020-04519-x

We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 ye...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033758/

Levodopa-induced dyskinesia (LID) is the most common, disruptive complication of Parkinson’s disease (PD) pharmacotherapy, yet despite decades of research, the changes in regional brain function underlying LID remain largely unknown. We previously found that the cerebral vasomotor and metabolic responses to levodopa are dissociated in PD subjects. Nonetheless, it is unclear whether levodopa-med...

Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700135/
Scientific Reports;

Chronic levodopa treatment leads to the appearance of dyskinesia in the majority of Parkinson’s disease patients. Neurovascular dysregulation in putaminal and pallidal regions is thought to be an underlying feature of this complication of treatment. We used microPET to study unilaterally lesioned 6-hydroxydopamine rats that developed levodopa-induced abnormal involuntary movements (AIMs) after ...

Lung ultrasound monitoring in patients with COVID-19 on home isolation
https://www.sciencedirect.com/science/article/pii/S073567572030440X

Many patients with COVID-19, the clinical illness caused by SARS-CoV-2 infection, exhibit mild symptoms and do not require hospitalization. Instead, these patients are often referred for 14-days of home isolation as symptoms resolve. Lung ultrasound is well-established as an important means of evaluating lung pathology in patients in the emergency department and in intensive care units. Ultraso...

Open Data
https://opendata.ncats.nih.gov/covid19/

NCATS is generating a collection of datasets by screening a panel of SARS-CoV-2-related assays against all approved drugs These datasets, as well as the assay protocols used to generate them, are being made immediately available to the scientific community on this site as these screens are completed

Antihypertensive drugs and risk of COVID-19?
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30153-3/fulltext
The Lancet Respiratory Medicine;

Mar 25th, 2020 - Lei Fang and colleagues1 suggest that clinicians should consider withholding angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) because of a potential increased risk of worse clinical outcomes in patients with coronavirus disease 2019 (COVID-19), and they suggest calcium channel blockers as an alternative. The hypothesis behind this suggestion is that the e...

SARS-CoV-2 Reference Panel Comparative Data
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data

The FDA SARS-CoV-2 Reference Panel allows for a more precise comparison of the analytical performance of different molecular in vitro diagnostic (IVD) assays intended to detect SARS-CoV-2. The Reference Panel contains common, independent, and well-characterized reference material that is available to developers of SARS-CoV-2 nucleic acid-based amplification tests (NAATs) for which Emergency Use...

Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html

As part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leading to the voluntary pause of vaccination across all trials to allow an independent committee to review the safety data of a single event of an unexplained illness that occurred in the UK Phase III trial. This is a routine act...

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd181565
Journal of Parkinson's Disease;

Jul 29th, 2019 - Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of Gocovri® (amantadine) extended release capsules on these episodes.

Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003)
https://n.neurology.org/content/88/16_Supplement/S56.003
Neurology

Apr 16th, 2017 - Data from two Phase 3 clinical studies investigating the efficacy and safety of ADS-5102 in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID) were pooled to summarize results for the shared primary endpoint, Unified Dyskinesia Rating Scale (UDysRS) and its sub-components.

New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200180/full/

May 28th, 2020 - DESKTOP III became the first phase III, prospective, randomized trial to show an association between improved overall survival (OS) and secondary cytoreductive surgery in women with platinum-sensitive recurrent ovarian cancer (PSROC), offering hope for people with a condition that results in nearly 14,000 deaths annually. Data were presented during the ASCO20 Virtual Scientific Program (Abstrac...

KarMMa: BCMA-Targeting CAR T Excellent Option for Relapsed/Refractory Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200194/full/

May 28th, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) resulted in deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to phase II data from the KarMMa trial (Abstract 8503).

Early Data Show Bispecific Antibody Teclistamab Safe, Active in Relapsed/Refractory Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200175/full/

May 28th, 2020 - Teclistamab, a IgG-4 bispecific antibody targeting BCMA and CD3, appears to be safe in patients with relapsed or refractory multiple myeloma, according to phase I data presented during the ASCO20 Virtual Scientific Program (Abstract 100).

Trastuzumab Fails to Improve DFS When Added to Trimodality Therapy for Operable Esophageal Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200178/full/

May 28th, 2020 - Although HER-targeted therapy represents a standard of care for many HER2-positive malignancies, data supporting its benefit for patients with early-stage HER2-overexpressing esophageal adenocarcinoma are lacking. Results of the RTOG 1010 trial demonstrated that adding trastuzumab both before and after chemoradiotherapy and surgery did not significantly improve disease-free survival (DFS) beyon...

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/German trial (Abstract 11503).

Off-the-shelf CAR-T regimen safe for advanced lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{87e5706a-8ecb-4473-95b8-60f27a6e22cb}/off-the-shelf-car-t-regimen-safe-for-advanced-lymphoma

May 31st, 2020 - An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.